Bimekizumab in patients with moderate to severe plaque psoriasis by bodyweight: Pooled results from phase 3 trials. (2022). SKIN The Journal of Cutaneous Medicine, 6(6), s73. https://doi.org/10.25251/skin.6.supp.73